|
|
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
|
1R01CA208644-01
|
$377,438
|
$377,438
|
CRITTENDEN, MARKA
|
PROVIDENCE PORTLAND MEDICAL CENTER
|
|
|
(PQ4) Mutations in the histone chaperone DAXX drive pancreatic neuroendocrine tumors not ductal adenocarcinomas
|
1R21CA208463-01
|
$208,800
|
$208,800
|
LOZANO, GUILLERMINA
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
|
5R01CA190092-03
|
$560,492
|
$560,492
|
TUVESON, DAVID
|
COLD SPRING HARBOR LABORATORY
|
|
|
(PQB-3) Driver gene-induced inflammation in pancreatic cancer development
|
5R01CA184926-03
|
$766,774
|
$766,774
|
JAFFEE, ELIZABETH
|
JOHNS HOPKINS UNIVERSITY
|
|
|
(PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer
|
5R01CA179991-04
|
$282,056
|
$282,056
|
IACOBUZIO-DONAHUE, CHRISTINE
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
|
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer
|
5R01CA185357-03
|
$470,355
|
$470,355
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
|
(PQD6) Muscle stem cells and cancer cachexia
|
4R01CA180057-04
|
$394,097
|
$394,097
|
GUTTRIDGE, DENIS
|
OHIO STATE UNIVERSITY
|
|
|
1/2: ""Feasibility Studies to Build Collaborative Partnerships in Reducing Racial/Ethnic Disparities in GI Cancer Research"" Minority Supplement 1
|
3P20CA192994-02S1
|
$200,001
|
$118,001
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
3P20CA192994-02S2
|
$63,140
|
$37,253
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
|
1/2: Partnership to study racial/ethnic differences in GI cancer biology
|
5P20CA192994-02
|
$289,027
|
$170,526
|
LI, ELLEN
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
|
2/2 Partnership to Study Racial/Ethnic Differences in GI Cancer Biology
|
5P20CA192996-02
|
$155,219
|
$100,892
|
MCCOMBIE, WILLIAM
|
COLD SPRING HARBOR LABORATORY
|
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
3U54CA132384-07S1
|
$199,986
|
$71,995
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132384-07
|
$1,082,983
|
$389,874
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
|
A cell-based liquid biopsy approach for early pancreatic cancer detection
|
5F32CA196120-02
|
$54,294
|
$54,294
|
BHAGWAT, NEHA
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
A Clinical Validation Center for Early Detection of Pancreatic Cancer
|
1U01CA200468-01
|
$794,418
|
$794,418
|
MAITRA, ANIRBAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
A Clinical Validation Center for Early Detection of Pancreatic Cancer
|
3U01CA200468-01S1
|
$254,464
|
$254,464
|
MAITRA, ANIRBAN
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
|
A Creative Integration of Omega-3 Fatty Acids into Pancreatic Cancer Chemotherapy
|
5R21CA179362-02
|
$202,928
|
$202,928
|
CUI, ZHENGRONG
|
UNIVERSITY OF TEXAS, AUSTIN
|
|
|
A differentiation-based mechanism limiting pancreatic tumor initiation
|
5F30CA192819-02
|
$40,185
|
$40,185
|
KRAH, NATHAN
|
UNIVERSITY OF UTAH
|
|
|
A new energy restriction mimetic that targets pancreatic cancer
|
5R21CA185276-02
|
$169,650
|
$169,650
|
LANZA-JACOBY, SUSAN
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
A novel combination approach for pancreatic cancer prevention
|
5R03CA181727-02
|
$79,000
|
$79,000
|
MACKENZIE, GERARDO
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
|
A novel miR-198 replacement therapy for pancreatic cancer
|
5R01CA183984-02
|
$473,915
|
$473,915
|
YAO, QIZHI
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A novel mouse model to identify biomarkers of IPMN formation and progression
|
5R21CA194839-02
|
$168,563
|
$168,563
|
SANDER, MAIKE
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
|
A novel regimen to target both pancreatic cancer K-ras and antiapoptotic proteins
|
5R03CA182552-02
|
$84,900
|
$84,900
|
LI, FENGZHI
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
|
A Prospective Investigation of the Oral Microbiome and Pancreatic Cancer
|
5U01CA187508-02
|
$562,163
|
$562,163
|
PALMER, JULIE
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
|
A role for macrophage phenotype in regulating metastasis in pancreatic carcinoma
|
5F30CA196106-02
|
$47,711
|
$47,711
|
LEE, JAE
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196-03152
|
$1,229,987
|
$61,499
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
|
Abramson Cancer Center Support Grant
|
2P30CA016520-40
|
$7,975,543
|
$319,022
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-40S1
|
$31,250
|
$1,250
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-40S2
|
$499,967
|
$19,999
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-40S3
|
$200,000
|
$8,000
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Advanced Development and Validation of 3 Dimensional Spheroid Culture of Primary Cancer Cells using Nano3D Technology
|
1R33CA206949-01
|
$501,426
|
$250,713
|
SPICER, TIMOTHY
|
SCRIPPS FLORIDA
|
|
|
Advanced Methods to Evaluate Extracellular Matrix and Crosslinking in the Tumor M
|
5R33CA183685-03
|
$379,434
|
$189,717
|
HANSEN, KIRK
|
UNIVERSITY OF COLORADO DENVER
|
|
|
AGX1/2 inhibitors as key modulators of the hexosamine biosynthetic pathway
|
5R21CA191715-02
|
$176,175
|
$176,175
|
YAREMA, KEVIN
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis
|
4R01CA164041-05
|
$320,525
|
$320,525
|
YANG, GUANG-YU
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S1
|
$1,595,651
|
$79,783
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S2
|
$550,000
|
$27,500
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S3
|
$750,000
|
$37,500
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-03
|
$9,068,022
|
$453,401
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
|
Alternatively Spliced Tissue Factor and Pathobiology of Pancreatic Cancer
|
5R01CA190717-02
|
$276,298
|
$276,298
|
BOGDANOV, VLADIMIR
|
UNIVERSITY OF CINCINNATI
|
|
|
An integrated computational and functional genomics discovery engine for preclini
|
4U01CA176303-04
|
$1,009,007
|
$332,972
|
KEMP, CHRISTOPHER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
|
Anatomic Pathology Residency Program
|
ZIE BC 011384
|
$1,014,935
|
$20,299
|
Barr, Frederic
|
CCR (NCI)
|
|
|
Annexin A2 as a mediator of pancreatic cancer metastases
|
4R01CA169702-04
|
$336,150
|
$336,150
|
ZHENG, LEI
|
JOHNS HOPKINS UNIVERSITY
|
|
|
Aptamers as Proteomic Tools for Pancreatic Cancer Biomarker Identification
|
5R21CA198287-02
|
$172,913
|
$172,913
|
WHITE, REBEKAH
|
DUKE UNIVERSITY
|
|
|
ATBC Study
|
ZIA CP010195-03031
|
$1,193,520
|
$155,158
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
|
ATDC Function in Human Pancreatic Adenocarcinoma
|
5R01CA131045-06
|
$368,125
|
$368,125
|
SIMEONE, DIANE
|
UNIVERSITY OF MICHIGAN
|
|
|
Basic and Preclinical Animal Models in support of Cancer and HIV-AIDS Research
|
ZIG BC 010856
|
$14,732,997
|
$736,650
|
Custer, Mary
|
CCR (NCI)
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S1
|
$118,016
|
$5,901
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S2
|
$170,897
|
$8,545
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S3
|
$118,875
|
$5,944
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-10S4
|
$499,947
|
$24,997
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Total relevant funding to Pancreas for this search: $152,555,852
|
